MDM2 and Wilson disease: Other CDK4/6 inhibitors, including the structurally distinct abemaciclib that is able to cross the blood-brain barrier,60 are currently under clinical investigation in WD/DDLPS as single agents or in combination with MDM2 or mTOR inhibitors (NCT02846987, NCT02343172, NCT03114527).